History
2020: Eli Lilly purchased Prevail Therapeutics for $1 billion
In the middle of December, 2020 Eli Lilly was included into ranks of the large pharmaceutical companies which are engaged in gene therapy, having paid $1 billion for Prevail Therapeutics company which develops two clinical programs.
The startup of Prevail was purchased in only three years after its basis by the investor Jonathan Silverstein. It started this project for fight against the Parkinson's disease (PD) caused by mutations in a gene of a glyukotserebrozidaza (GBA1).
The leading medicine developed by a startup (PR001) passed into the 2nd phase of a research and will be applied at patients with GBA1 positive BP and also a neyropatichesky disease to Gosha, and the second candidate (PR006) - at patients with frontal and temporal dementia in the presence of mutations is GRN.
At a preclinical stage of researches there is also some other medicines of gene therapy, including candidates for treatment of group of the neurodegenerative statuses famous as sinukleinopatiya and also Alzheimer's disease and a side amyotrophic sclerosis.
The stocks Prevail sharply rose after the declaration of the transaction. Eli Lilly is ready to pay $22.50 for an action and also payment within a shareholder right on the mezzanine board at a company takeover (CVR) in the amount of $4 for an action if any of the medicines Prevail gets approval of regulating authorities until the end of 2024. After that the cost of CVR will be steadily fall before the expiration of its action at the end of 2028.
 | Gene therapy - promising approach to treatment of patients with neurodegenerative diseases, such as Parkinson's disease, disease to Gosha and dementia, - the vice president for researches of pain and a neurodegeneration in Lilly Mark Mintun noted. - Important technology achievements and the highly skilled Prevail commands will add Lilly experience, and we will be able to develop the new program of gene therapy, relying on well studied assets.[1] |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |